Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Darnall

Sleep Medicine Austin, TX Medical Doctor

NPI 1225204530 CMS profile 996306

11714 Wilson Parke Ave Ste 150, Austin, TX 78726

Open in the dashboard

General payments

$540

4 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Darnall of Austin, TX is reported in the CMS Open Payments database as having received $540 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $150 1
2024 General $175 1
2021 General $150 1
2019 General $64 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Darnall
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Christopher Darnall were reported at $150. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Christopher Darnall Sleep Medicine median Middle half National median
2019 $64 $206 $79–$855 $163
2020 $0 $170 $48–$1,437 $114
2021 $150 $178 $53–$1,297 $132
2022 $0 $313 $95–$1,332 $149
2023 $0 $307 $117–$1,081 $160
2024 $175 $308 $100–$1,432 $164
2025 $150 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $326 2 payments
  2. Jazz Pharmaceuticals Inc. $214 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $390 3 payments
  2. Consulting Fee $150 1 payment
Products named General payments · program years 2019–2025
  1. XYREM $214 2 payments
  2. INSPIRE $175 1 payment
  3. Inspire Upper Airway Stimulation System $150 1 payment
  4. XYWAV $150 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

423

Median for Neurology: 833

Drug cost

$9,581

Median for Neurology: $202,670

Branded share of claims

15.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxepin Hcl Generic 12 $1,990
Armodafinil Generic 16 $1,589
Modafinil Generic 32 $1,153
Ramelteon Generic 19 $1,136
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 64 $973
Eszopiclone Generic 68 $812
Mirtazapine Generic 16 $415
Methylphenidate Hcl Generic 12 $393
Trazodone Hcl Generic 57 $345
Gabapentin Generic 42 $276

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$234,947

Medicare's payments for the services billed

Medicare patients

1,347

Average age 74

Services billed

2,081

612 women, 735 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 37%
Diabetes 34%
Atrial fibrillation 24%
Depression 22%
Chronic kidney disease 17%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record